Studies in patients with non-small lung carcinoma (NSCLC), gastric cancer, and CRC reported co-expression of HLA-G and its receptors ILT2 or ILT4 on tumor cells, and showed a correlation between co-expression and poor clinical outcome [79,80,81]. Here, LILRB2 is linked to non-small cell lung carcinoma.